Masahiro Tajika

24PUBLICATIONS
97CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Social epidemiologyPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Modelling and simulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 24, 2026
Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5-Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single-Institute Propensity Score Analysis.

|Apr 09, 2026
Risk Factors for Metastasis and Prognosis in Non-Curative Resection After Endoscopic Submucosal Dissection for Undifferentiated-Type Early Gastric Cancer in a Nationwide Cohort in Japan.

Kazuo Shiotsuki, Kohei Takizawa, Akifumi Notsu

|Dec 14, 2024
Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study.

Yukiya Narita, Taro Mizuno, Yasunobu Ishizuka

|Jan 26, 2024
Genetic architecture of alcohol consumption identified by a genotype-stratified GWAS and impact on esophageal cancer risk in Japanese people.

Yuriko N Koyanagi, Masahiro Nakatochi, Shinichi Namba

|Nov 21, 2023
Short-term outcomes of endoscopic resection for colorectal neuroendocrine tumors: Japanese multicenter prospective C-NET STUDY.

Sayo Ito, Kinichi Hotta, Masau Sekiguchi

|Nov 14, 2023
Skeletal Muscle Quality and Quantity Affect Prognosis after Neoadjuvant Chemotherapy with a Triple Regimen of Docetaxel/Cisplatin/5-FU in Patients with Esophageal Cancer.

Nobuhito Ito, Masahiro Tajika, Tsutomu Tanaka

Pageof 4

Frequent Collaborators

3 joint publications

Kei Muro

2 joint publications

Yukiya Narita

2 joint publications

Daisuke Takahari

2 joint publications

Koji Komori